Jafron Haemoadsorption During Cardiopulmonary Bypass
Status:
Not yet recruiting
Trial end date:
2022-09-15
Target enrollment:
Participant gender:
Summary
Cardiopulmonary bypass (CPB) is often associated with degrees of complex inflammatory
response mediated by various cytokines. This response can, in severe cases, lead to systemic
hypotension and organ dysfunction. Cytokine removal might therefore improve outcomes of
patients undergoing cardiac surgery. Jafron is a device designed to remove cytokine from the
blood using haemoadsorption (HA). This preliminary report aims to evaluate the potential of
Jafron to decrease peri-operative cytokine levels in cardiac surgery.